Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2018

18.04.2018 | Laboratory Investigation

Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines

verfasst von: Mirella Baroni, Suely Kazue Nagahashi Marie, Paola Fernanda Fedatto, Augusto Faria Andrade, Veridiana Kill Suazo, Gustavo Alencastro Veiga Cruzeiro, Rosane de Paula Queiroz, Luiz Gonzaga Tone, Carlos Alberto Scrideli

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Glioblastoma (GBM) is the most common malignant primary brain tumor affecting adults. In pediatric patients, GBM exhibits genetic variations distinct from those identified in the adult GBM phenotype. This tumor exhibits complex genetic changes leading to malignant progression and resistance to standard therapies including radiotherapy and temozolomide treatment. The GDF15 gene codes for a growth factor whose expression is altered in the presence of inflammations and malignancies. GDF15 is associated with a poor prognosis and with radio- and chemoresistance in a variety of tumors. The aim of this study was to compare the response to GDF15 knockdown in adult (U343) and pediatric (KNS42) GBM cell line models.

Methods

The expression of the GDF15 gene was investigated by qRT-PCR and overexpression was identified in both GBM cell lines. The KNS42 and U343 cell lines were submitted to lentiviral transduction with shRNA of GDF15 and validated at the protein level. To understand the difference between cell lines, RNAseq was performed after GDF15 knockdown.

Results

The data obtained demonstrated that the pathways were differentially expressed in adult GBM and pediatric GBM cell lines. This was confirmed by functional assays perfomed after independent treatments (radiotherapy and TMZ).

Conclusion

These results demonstrated that GBM cell lines had distinct responses to GDF15 knockdown, a fact that can be explained by the different molecular profile of pediatric and adult GBM.
Literatur
1.
Zurück zum Zitat Jue TR, McDonald KL (2016) The challenges associated with molecular targeted therapies for glioblastoma. J Neurooncol 127:427–434CrossRefPubMed Jue TR, McDonald KL (2016) The challenges associated with molecular targeted therapies for glioblastoma. J Neurooncol 127:427–434CrossRefPubMed
2.
Zurück zum Zitat Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, Iavarone A, Aldape K, Brennan CW, Jabado N, Pfister SM (2014) Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14:92–107CrossRefPubMedPubMedCentral Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, Iavarone A, Aldape K, Brennan CW, Jabado N, Pfister SM (2014) Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14:92–107CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefPubMed Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefPubMed
7.
Zurück zum Zitat Baker SJ, Ellison DW, Gutmann DH (2016) Pediatric gliomas as neurodevelopmental disorders. Glia 64:879–895PubMed Baker SJ, Ellison DW, Gutmann DH (2016) Pediatric gliomas as neurodevelopmental disorders. Glia 64:879–895PubMed
8.
Zurück zum Zitat Broniscer A, Tatevossian RG, Sabin ND, Klimo P Jr, Dalton J, Lee R, Gajjar A, Ellison DW (2014) Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol 40:327–336CrossRefPubMedPubMedCentral Broniscer A, Tatevossian RG, Sabin ND, Klimo P Jr, Dalton J, Lee R, Gajjar A, Ellison DW (2014) Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol 40:327–336CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. 2015 Acta Neuropathol; 129:669–678 Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. 2015 Acta Neuropathol; 129:669–678
10.
Zurück zum Zitat Scrideli CA, Carlotti CG, Okamoto OK et al (2008) Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol 88:281–291CrossRefPubMed Scrideli CA, Carlotti CG, Okamoto OK et al (2008) Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol 88:281–291CrossRefPubMed
11.
Zurück zum Zitat Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M, Wischhusen J (2010) GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 16:3851–3859CrossRefPubMed Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M, Wischhusen J (2010) GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 16:3851–3859CrossRefPubMed
12.
Zurück zum Zitat Li J, Veltri RW, Yuan Z, Christudass CS, Mandecki W (2015) Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer. PLoS ONE 10:e0122249CrossRefPubMedPubMedCentral Li J, Veltri RW, Yuan Z, Christudass CS, Mandecki W (2015) Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer. PLoS ONE 10:e0122249CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Li C, Wang X, Casal I, Wang J, Li P, Zhang W, Xu E, Lai M, Zhang H (2016) Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med 20:1420–1426CrossRefPubMedPubMedCentral Li C, Wang X, Casal I, Wang J, Li P, Zhang W, Xu E, Lai M, Zhang H (2016) Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med 20:1420–1426CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W (2014) Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer 14:578CrossRefPubMedPubMedCentral Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W (2014) Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer 14:578CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Zhang Y, Hua W, Niu LC, Li SM, Wang YM, Shang L, Zhang C, Li WN, Wang R, Chen BL, Xin XY, Zhang YQ, Wang J (2016) Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients. Tumour Biol 37:9423–9431CrossRefPubMed Zhang Y, Hua W, Niu LC, Li SM, Wang YM, Shang L, Zhang C, Li WN, Wang R, Chen BL, Xin XY, Zhang YQ, Wang J (2016) Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients. Tumour Biol 37:9423–9431CrossRefPubMed
16.
Zurück zum Zitat Shimizu S, Kadowaki M, Yoshioka H, Kambe A, Watanabe T, Kinyamu HK, Eling TE (2013) Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells. Biochem Biophys Res Commun 430:1277–1282CrossRefPubMed Shimizu S, Kadowaki M, Yoshioka H, Kambe A, Watanabe T, Kinyamu HK, Eling TE (2013) Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells. Biochem Biophys Res Commun 430:1277–1282CrossRefPubMed
17.
Zurück zum Zitat Eling TE, Baek SJ, Shim M et al (2006) NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 39:649–655PubMed Eling TE, Baek SJ, Shim M et al (2006) NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 39:649–655PubMed
18.
Zurück zum Zitat Corre J, Labat E, Espagnolle N et al (2012) Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by boné marrow mesenchymal stem cells in multiple myeloma. Cancer Res 72:1395–1406CrossRefPubMed Corre J, Labat E, Espagnolle N et al (2012) Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by boné marrow mesenchymal stem cells in multiple myeloma. Cancer Res 72:1395–1406CrossRefPubMed
19.
Zurück zum Zitat Unsicker K, Spittau B, Krieglstein K (2013) The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 24:373–384CrossRefPubMed Unsicker K, Spittau B, Krieglstein K (2013) The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 24:373–384CrossRefPubMed
20.
Zurück zum Zitat Wang X, Baek SJ, Eling TE (2013) The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem Pharmacol 85:597–606CrossRefPubMed Wang X, Baek SJ, Eling TE (2013) The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem Pharmacol 85:597–606CrossRefPubMed
21.
Zurück zum Zitat Strelau J, Schmeer C, Peterziel H, Sackmann T, Herold-Mende C, Steiner H, Weller M, Unsicker K (2008) Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. Cancer Lett 270:30–39CrossRefPubMed Strelau J, Schmeer C, Peterziel H, Sackmann T, Herold-Mende C, Steiner H, Weller M, Unsicker K (2008) Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. Cancer Lett 270:30–39CrossRefPubMed
22.
Zurück zum Zitat Codó P, Weller M, Kaulich K, Schraivogel D, Silginer M, Reifenberger G, Meister G, Roth P (2016) Control of glioma cell migration and invasiveness by GDF-15. Oncotarget 7:7732–7746CrossRefPubMedPubMedCentral Codó P, Weller M, Kaulich K, Schraivogel D, Silginer M, Reifenberger G, Meister G, Roth P (2016) Control of glioma cell migration and invasiveness by GDF-15. Oncotarget 7:7732–7746CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Zhang Z, Wu L, Wang J, Li G, Feng D, Zhang B, Li L, Yang J, Ma L, Qin H (2014) Opposing effects of PI3K/Akt and Smad-dependent signaling pathways in NAG-1-induced glioblastoma cell apoptosis. PLoS ONE 9:e96283CrossRefPubMedPubMedCentral Zhang Z, Wu L, Wang J, Li G, Feng D, Zhang B, Li L, Yang J, Ma L, Qin H (2014) Opposing effects of PI3K/Akt and Smad-dependent signaling pathways in NAG-1-induced glioblastoma cell apoptosis. PLoS ONE 9:e96283CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Kadowaki M, Yoshioka H, Kamitani H, Watanabe T, Wade PA, Eling TE (2012) DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int J Cancer 130:267–277CrossRefPubMed Kadowaki M, Yoshioka H, Kamitani H, Watanabe T, Wade PA, Eling TE (2012) DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int J Cancer 130:267–277CrossRefPubMed
25.
Zurück zum Zitat Shnaper S, Desbaillets I, Brown DA, Murat A, Migliavacca E, Schluep M, Ostermann S, Hamou MF, Stupp R, Breit SN, de Tribolet N, Hegi ME (2009) Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer 125:2624–2630CrossRefPubMed Shnaper S, Desbaillets I, Brown DA, Murat A, Migliavacca E, Schluep M, Ostermann S, Hamou MF, Stupp R, Breit SN, de Tribolet N, Hegi ME (2009) Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer 125:2624–2630CrossRefPubMed
26.
Zurück zum Zitat Yoshioka H, Kamitani H, Watanabe T, Eling TE (2008) Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem 283:33129–33137CrossRefPubMedPubMedCentral Yoshioka H, Kamitani H, Watanabe T, Eling TE (2008) Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem 283:33129–33137CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Huang CY, Beer TM, Higano CS et al (2007) Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation fator 15. Clin Cancer Res 13:5825–5833CrossRefPubMed Huang CY, Beer TM, Higano CS et al (2007) Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation fator 15. Clin Cancer Res 13:5825–5833CrossRefPubMed
28.
Zurück zum Zitat St-Coeur PD, Touaibia M, Cuperlovic-Culf M, Morin P Jr (2013) Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas. Genom Proteom Bioinform 11:199–206CrossRef St-Coeur PD, Touaibia M, Cuperlovic-Culf M, Morin P Jr (2013) Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas. Genom Proteom Bioinform 11:199–206CrossRef
29.
Zurück zum Zitat Wang Q, Du J, Xu B, Xu L, Wang X, Liu J, Wang J (2016) Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway. Acta Biochim Biophys Sin (Shanghai) 48:501–508CrossRef Wang Q, Du J, Xu B, Xu L, Wang X, Liu J, Wang J (2016) Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway. Acta Biochim Biophys Sin (Shanghai) 48:501–508CrossRef
30.
Zurück zum Zitat Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R, Basso G (2012) BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis 3:e412CrossRefPubMedPubMedCentral Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R, Basso G (2012) BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis 3:e412CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Chen W, Xiao Z, Zhao Y, Huang L, Du G (2013) HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. Oncol Rep 30:2495–2501CrossRefPubMed Chen W, Xiao Z, Zhao Y, Huang L, Du G (2013) HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. Oncol Rep 30:2495–2501CrossRefPubMed
32.
Zurück zum Zitat Ströbele S, Schneider M, Schneele L, Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Westhoff MA, Halatsch ME, Debatin KM (2015) A potential role for the Inhibition of PI3K signaling in glioblastoma therapy. PLoS ONE 10:e0131670CrossRefPubMedPubMedCentral Ströbele S, Schneider M, Schneele L, Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Westhoff MA, Halatsch ME, Debatin KM (2015) A potential role for the Inhibition of PI3K signaling in glioblastoma therapy. PLoS ONE 10:e0131670CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Wickström M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool M, Kogner P, Baryawno N, Johnsen JI (2015) Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun 6:8904CrossRefPubMedPubMedCentral Wickström M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool M, Kogner P, Baryawno N, Johnsen JI (2015) Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun 6:8904CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C, Cohen-Jonathan-Moyal E (2013) Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible fator 1 alpha and survivin in U87 cells. Eur J Cancer 49:2884–2891CrossRefPubMed Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C, Cohen-Jonathan-Moyal E (2013) Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible fator 1 alpha and survivin in U87 cells. Eur J Cancer 49:2884–2891CrossRefPubMed
36.
Zurück zum Zitat Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LM, van Hoof SJ, Groot AJ, Habets R, Prickaerts J, Chalmers AJ, Eekers DB, Theys J, Short SC, Verhaegen F, Vooijs M (2016) NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget 7:41251–41264PubMedPubMedCentral Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LM, van Hoof SJ, Groot AJ, Habets R, Prickaerts J, Chalmers AJ, Eekers DB, Theys J, Short SC, Verhaegen F, Vooijs M (2016) NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget 7:41251–41264PubMedPubMedCentral
37.
Zurück zum Zitat Chiang MF, Chen HH, Chi CW, Sze CI, Hsu ML, Shieh HR, Lin CP, Tsai JT, Chen YJ (2015) Modulation of Sonic hedgehog signaling and WW domain containing oxidoreductase WOX1 expression enhances radiosensitivity of human glioblastoma cells. Exp Biol Med (Maywood) 240:392–399CrossRef Chiang MF, Chen HH, Chi CW, Sze CI, Hsu ML, Shieh HR, Lin CP, Tsai JT, Chen YJ (2015) Modulation of Sonic hedgehog signaling and WW domain containing oxidoreductase WOX1 expression enhances radiosensitivity of human glioblastoma cells. Exp Biol Med (Maywood) 240:392–399CrossRef
38.
Zurück zum Zitat Dong Z, Zhou L, Han N, Zhang M, Lyu X (2015) Wnt/β-catenin pathway involvement in ionizing radiation-induced invasion of U87 glioblastoma cells. Strahlenther Onkol 191:672–680CrossRefPubMed Dong Z, Zhou L, Han N, Zhang M, Lyu X (2015) Wnt/β-catenin pathway involvement in ionizing radiation-induced invasion of U87 glioblastoma cells. Strahlenther Onkol 191:672–680CrossRefPubMed
39.
Zurück zum Zitat Chang JTC, Chan SH, Lin CY et al (2007) Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 6:2271–2279CrossRefPubMed Chang JTC, Chan SH, Lin CY et al (2007) Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 6:2271–2279CrossRefPubMed
Metadaten
Titel
Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines
verfasst von
Mirella Baroni
Suely Kazue Nagahashi Marie
Paola Fernanda Fedatto
Augusto Faria Andrade
Veridiana Kill Suazo
Gustavo Alencastro Veiga Cruzeiro
Rosane de Paula Queiroz
Luiz Gonzaga Tone
Carlos Alberto Scrideli
Publikationsdatum
18.04.2018
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-2853-1

Weitere Artikel der Ausgabe 1/2018

Journal of Neuro-Oncology 1/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.